Загрузка...
A Phase I Study of Bevacizumab (B) in Combination with Everolimus (E) and Erlotinib (E) in Advanced Cancer (BEE)
PURPOSE: VEGF, mTOR, and EGFR inhibitors have demonstrated anti-tumor and anti-angiogenic effects alone and in combination with each other. This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus and erlotinib combination. METHODS: Doublet therapy consisted of...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4086252/ https://ncbi.nlm.nih.gov/pubmed/21079958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1507-6 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|